Fungal infections in neutropenic cancer patients have increased in frequency and constitute an important cause of morbidity and mortality. Empiric antifungal therapy is often administered to those patients who have failed to respond to antibacterial antibiotics. We conducted a prospective, randomized trial of amphotericin B and ketoconazole for 172 neutropenic cancer patients with presumed or proven fungal infections. Overall, amphotericin B and ketoconazole were equally effective. Amphotericin B may have been more effective than ketoconazole for the treatment of pneumonia. Also,' five of eight Candida tropicalis infections treated with amphotericin B responded, whereas all eight infections treated with ketoconazole failed to respond (P = 0.03). Response rates for localized fungal infections were similar with both drugs. Ketoconazole should not be used as empiric antifungal therapy at institutions where there is a high frequency of infections caused by Aspergillus spp. or C. tropicalis because this agent lacks activity in vitro against these species.
Fungal infections are increasing in frequency among neutropenic cancer patients (1, 4, 5, 7, 9) . Many of these infections cannot be diagnosed antemortem; hence, the patients never receive antifungal therapy. For this reason, it has become accepted practice to administer antifungal agents empirically to neutropenic patients with persistent fever that is unresponsive to antibacterial agents.
Amphotericin B has been the mainstay of antifungal therapy. Unfortunately, it has many unpleasant side effects that make it an undesirable agent for empiric therapy. Ketoconazole, a new imidazole derivative, is an appealing substitute for amphotericin B because it is less toxic and is administered orally. However, its spectrum of antifungal activity does not include Aspergillus spp. and Candida tropicalis. We conducted the first prospective, randomized trial of amphotericin B and ketoconazole for the treatment of established or suspected fungal infections in neutropenic cancer patients.
MATERIALS AND METHODS
Patient eligibility. Between 1981 and 1983, neutropenic cancer patients having persistent fever (temperature > 38.3°C) after 72 to 96 h of therapy with antibacterial antibiotics were considered eligible for study participation. Patients with clinically suspected or microbiologically proven fungal disease were also included. Patients with significant hepatic impairment (bilirubin, >5 mg/dl) or renal insufficiency (creatinine, >2.5 mg/dl) were not included. All eligible patients had to be capable of taking oral medications or have functional nasogastric tubes. Initial therapy with antibacterial antibiotics was discontinued for all patients in this study. Cimetidine and antacids were discontinued before therapy was started in patients selected to receive ketoconazole. Patients who were receiving concomitant oral nystatin for thrush or esophagitis were not considered for evaluation.
Leukocyte transfusions were given to those patients who had available donors and in whom a microbiologically * Corresponding author. proven infection had been documented but who yet remained febrile and clinically ill after institution of antifungal therapy.
Treatment regimens. Eligible patients were given either amphotericin B or ketoconazole as determined by a computer-generated randomization schedule. After allocation, all previous antibacterial antibiotics were discontinued. All patients in the study received trimethoprim-sulfamethoxazole if they had an undocumented bacterial infection. For the antifungal agents, the dosage schedules were as follows: ketoconazole was given orally at a dose of 200 mg every 6 h (1 h before or 2 h after meals); amphotericin B (1 mg) was given as a test dose on day 1, followed by 0.5 mg/kg intravenously (i.v.) on day 2 and 0.6 to 1.0 mg/kg on a daily basis thereafter. The dose of amphotericin B was reduced if the serum creatinine reached 2.5 mg/dl, and treatment was discontinued at levels greater than 4 mg/dl. Trimethoprim (480 mg/day) and sulfamethoxazole (2,400 mg/day) were given either orally or i.v. in divided doses once every 8 h.
Patients were made aware of the investigational nature of the study and signed an informed-consent document according to institutional policies.
Patients were evaluated after they had received antifungal therapy for at least 4 days. In those patients responding to therapy, antifungal agents were continued for a minimum of 2 weeks. None of those eligible for evaluation had received trimethoprim-sulfamethoxazole or antifungal therapy before entering the study. Patients were considered cured when all clinical and microbiologic signs and symptoms of infection had been eradicated, and treatments were considered failures when those signs and symptoms persisted despite therapy for at least 7 days. The persistence of fever alone was defined as treatment failure only among patients with possible infections. In those patients with documented infections, persistence of fever was not considered a treatment failure if signs and symptoms of infection were resolved. Although crossover therapy was not included as part of this study, patients who failed to respond to their assigned regimens were occasionally treated subsequently with the other antifungal agent. (58%) than to ketoconazole (38%); however, this difference was not statistically significant (P = 0.61). The difference in outcome was at least in part due to the poor response to ketoconazole for patients with fungemia caused by C. tropicalis. Three patients with fungemia who did not respond to ketoconazole subsequently responded to amphotericin B. The three disseminated infections treated with amphotericin B were caused by Candida albicans, C. tropicalis, and Trichosporon cutaneum in combination with C. tropicalis; treatment failed for these patients. The four disseminated infections treated with ketoconazole were all caused by C. tropicalis; treatment failed for all four patients, although two of them subsequently responded to amphotericin B. Response rates for pneumonia and esophagitis were lower among patients treated with ketoconazole than among those treated with amphotericin B; however, these differences were not statistically significant.
The response rates for infections caused by C. albicans and other Candida spp. were similar with both ketoconazole and amphotericin B (Table 4) . However, a substantial difference in response rates was observed for patients infected with C. tropicalis, with five of eight episodes (63%) of infection responding to amphotericin B therapy, as opposed to none responding to ketoconazole therapy (P = 0.03). The few Aspergillus infections treated failed to respond to either drug.
The response to therapy was analyzed by changes in absolute neutrophil counts during therapy ( Table 5 ). The response rate to amphotericin B was better overall for those patients whose neutrophil count increased than for those whose count decreased or remained unchanged during ther- apy (P = 0.03); the duration of neutropenia in these patients before initiation of antifungal therapy was not recorded. Amphotericin B was more effective than ketoconazole for those patients whose neutrophil count increased (81 versus 54%; P = 0.06). There was no difference in efficacy between the two drugs for patients whose neutrophil count decreased or remained unchanged.
Forty-six patients received leukocyte transfusions during the course of infection. Of the 46, 34 patients received from one to four transfusions; 12 of 20 transfusion recipients treated with amphotericin B responded (60%), and 5 of 14 recipients treated with ketoconazole responded (36%). Twelve more patients received from 5 to 12 transfusions: three of eight treated with amphotericin B responded (38%), and two of four treated with ketoconazole responded (50%).
Eight patients developed nausea and vomiting attributed to ketoconazole, which was severe enough to prompt discontinuation of the drug. In seven patients, fever and bronchospasm induced by amphotericin B were so severe that they became dose-limiting factors. Adequate liver and renal function tests were available for analysis during eval- (Table 6) . Increases in alkaline phosphatase occurred more frequently among patients receiving amphotericin B (43 versus 21%; P = 0.06). Although elevations of serum glutamic oxalacetic transaminase occurred with similar frequency in both treatment groups, patients receiving ketoconazole for more than 2 weeks experienced toxicity more frequently than did those treated with shorter courses (39 versus 15%; P = 0.11).
Renal toxicity was detected in 41 patients. A statistically significant difference was observed between those who received amphotericin B and those who received ketoconazole (41 versus 9%; P = <0.001). There was no relation between dosage of amphotericin B and the incidence of nephrotoxicity. For those patients with amphotericin B-induced renal insufficiency, the median dose administered was 330 mg (range, 100 mg to 1 g), and for those without toxicity, the median dose was 380 mg (range, 70 mg to 1 g). The frequency of renal toxicity was also unrelated to the duration of therapy (Table 6 ). A significant difference in nephrotoxicity was observed among patients receiving ketoconazole for less than 14 days versus those receiving longer therapy. The elevations of creatinine values for these patients probably were not related to the drug, since all patients demonstrating renal toxicity also exhibited some degree of liver dysfunction, perhaps as a result of the infectious and neoplastic processes.
DISCUSSION
There are several difficulties in designing a prospective study to evaluate therapy of fungal infections in neutropenic patients. Clinicians who care for these individuals are familiar with many of these frustrating problems; perhaps that is why no large studies comparing amphotericin B with ketoconazole have been conducted. The frequency of proven fungal infections is low, and invasive diagnostic procedures seldom can be performed for documentation without subjecting the patient to substantial risks. Antibacterial regimens induce changes in normal flora, resulting in fungal overgrowth, and so add to the diagnostic uncertainties (2, 3, 13) . Finally, there are few therapeutic alternatives, and toxicity and mortality rates are often high. Because of these adverse circumstances, management strategies vary from institution to institution, and many therapeutic regimens are instituted on an empiric basis.
The difficulty in documenting fungal infections was again encountered during this study. Of 158 evaluatable episodes, fungal infection was documented in only 29 (18%), a proportion which closely resembles previously reported figures (4) . Interestingly, a better response rate was obtained with patients whose fungal infection could not be documented than in those with histologically proven infection. These response rates could reflect either the treatment effect before substantial tissue invasion or the absence of fungal infection.
Fungemia without clinical evidence of tissue invasion was considered a probable fungal infection as defined in this study. All of these patients had intravascular catheters at the time the fungus was cultured from their blood. Although we recommend removal of catheters under these circumstances, this was done with only three of the patients. The usual practice at most institutions is to remove the catheter without administering antifungal therapy. However, Rose reported that 9 of 35 patients with catheter-associated candidemia had persistent positive blood cultures after the catheter was removed and thus required antifungal therapy (11) . In a study of 82 cancer patients with candidemia, the mortality was 77%; of those who underwent autopsy examination, 71% had histological evidence of candidiasis. Furthermore, some patients whose catheters had been removed but who received no antifungal therapy returned at a later date with documentable fungal infection. Hence, it is likely that some of our patients may also have had undetected disseminated candidiasis.
Candida spp. still remain the most common causes of fungal infection at our institution. The ratio of C. tropicalis to C. albicans infections has increased in recent years (6, 12) . Of interest is the fact that there were equal numbers of major infections caused by the two species. While the response rate for C. albicans was similar in both arms of the study, a striking difference was noted in those patients infected with C. tropicalis. None of the patients treated with ketoconazole responded, whereas five of eight who had received amphotericin B responded. Moody et al. have previously reported the suboptimal in vitro activity of ketoconazole against C. tropicalis (8). At our institution, C. albicans was the predominant fungal pathogen in neutropenic patients prior to the initiation of this study; this was one of the reasons that our comparative trial of amphotericin B and ketoconazole was conducted. However, in institutions where Aspergillus spp., C. tropicalis, and Mucor spp. are common pathogens, ketoconazole should not be used since this compound has minimal therapeutic activity against these species.
The proper treatment for a neutropenic patient who has no focal signs of infection and yet remains febrile despite broad-spectrum antibiotic therapy remains uncertain. We have used antifungal therapy empirically for many of these patients since 1966. However, there are many possible causes of persistent fever in these patients (e.g., drugs, resistant bacterial infections, and the malignant process itself). Pizzo et al. (10) conducted a prospective, randomized study among patients who failed to respond to carbenicillin, cephalothin, and gentamicin. Patients continued the same therapy, discontinued antimicrobial therapy, or received amphotericin B in addition. The best results were obtained when amphotericin B was added (10) .
Trimethoprim-sulfamethoxazole was given to all of the patients in our study because we recognized that persistent fever could be due to bacterial infections. Although we were able to prove the presence of bacterial infection in only eight patients, it is possible that some of the responses attributed to the antifungal agent were really due to trimethoprimsulfamethoxazole. Furthermore, we were concerned that some patients might develop bacterial superinfections during antifungal therapy if all antibacterial therapy was discontinued. In our previous experience, patients have died unexpectedly as a result of an unrecognized bacterial infection during treatment of a proven fungal infection. Consequently, we believed that it was inappropriate to discontinue all antibacterial treatment in these patients, despite possible complications for interpretation of the results. In any case, there is no evidence that a systematic bias influenced the comparison of amphotericin B and ketoconazole.
The most important toxic effect of amphotericin B was renal insufficiency, which developed in 34 patients treated with this drug. The renal abnormalities found in patients treated with ketoconazole were probably the result of disseminated infection, renal involvement, septic shock, or poor renal perfusion (which many of these patients developed), rather than true drug-induced nephrotoxicity. Until better diagnostic procedures become available or new, less toxic antifungal agents are discovered, many patients with suspected fungal infection will be exposed to amphotericin B on an empiric basis, thereby risking undesirable side effects.
We used a higher dose of ketoconazole than is usual to make sure that we achieved adequate and useful therapeutic levels. The major toxic effect among patients treated with ketoconazole in this study was an asymptomatic increase in serum glutamic oxalacetic transaminase. Liver function test abnormalities are common findings in these acutely ill patients. Sometimes it is extremely difficult to distinguish the cause of these abnormalities since they can be related to the underlying malignancy, toxicity of antimicrobial agents, septicemia, or fungal involvement of the liver.
This study failed to detect significant therapeutic differences between amphotericin B and ketoconazole except for infections caused by C. tropicalis. Neither agent was effective against disseminated fungal infection. This confirms our previous observation that the most critical factor in response to fungal infection is recovery of the neutrophil count. Because of the limitations of ketoconazole, amphotericin B was more useful for empiric therapy of suspected fungal infection.
